Which medications are contraindicated in patients undergoing dialysis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medications Contraindicated or Requiring Adjustment in Dialysis Patients

No medications are absolutely contraindicated in all dialysis patients, but several drug classes require dose adjustments, frequency changes, or should be avoided due to accumulation risk and toxicity. The key principle is that renally-cleared medications accumulate and require dosing modifications, while hepatically-metabolized drugs generally do not 1.

Medications to Avoid or Use with Extreme Caution

Absolutely Avoid

  • Gadolinium-containing contrast media in patients with GFR <15 mL/min/1.73 m² (dialysis patients) unless no alternative exists, due to risk of nephrogenic systemic fibrosis 1
  • Oral phosphate-containing bowel preparations - contraindicated due to risk of phosphate nephropathy 1
  • Metformin - contraindicated in dialysis patients (GFR <30 mL/min/1.73 m²) due to lactic acidosis risk 1, 2
  • Glyburide/glibenclamide - avoid due to prolonged hypoglycemia risk from renally-excreted metabolites 1

High-Risk Medications Requiring Extreme Caution

  • NSAIDs - avoid in dialysis patients; associated with bleeding risk and cardiovascular complications 1
  • Enoxaparin and eptifibatide - contraindicated/not recommended; associated with 66% increased bleeding risk in dialysis patients undergoing procedures 3
  • Morphine and codeine - avoid due to accumulation of active metabolites causing neurotoxicity and respiratory depression 4

Medications Requiring Dose Adjustment

Antimicrobials

Aminoglycosides (streptomycin, kanamycin, amikacin, capreomycin):

  • Change to 12-15 mg/kg dose 2-3 times weekly (NOT daily)
  • Give after hemodialysis
  • Monitor serum levels (trough and peak)
  • Avoid concomitant ototoxic agents 5, 6

Fluoroquinolones:

  • Levofloxacin: 750-1000 mg three times weekly (NOT daily) 5, 6
  • Reduce dose by 50% when GFR <15 mL/min/1.73 m² 1

Other antimicrobials:

  • Macrolides: reduce dose by 50% 1
  • Penicillin: risk of neurotoxicity with high doses (maximum 6 g/day) 1
  • Tetracyclines: reduce dose; can exacerbate uremia 1
  • Fluconazole: reduce maintenance dose by 50% 1

Antituberculosis Medications

Require frequency adjustment (give three times weekly, NOT daily):

  • Pyrazinamide: 25-35 mg/kg per dose
  • Ethambutol: 15-25 mg/kg per dose
  • Cycloserine: 250 mg once daily or 500 mg three times weekly
  • Injectable agents (streptomycin, capreomycin, kanamycin, amikacin): 12-15 mg/kg 2-3 times weekly 5, 6

No adjustment needed:

  • Isoniazid and rifampin (hepatically metabolized) 5, 6

Cardiovascular Medications

  • Beta-blockers: reduce dose by 50% 1
  • Digoxin: reduce dose based on plasma concentrations 1
  • Low-molecular-weight heparins: halve the dose; consider switching to unfractionated heparin 1
  • Warfarin: use lower doses with close monitoring due to increased bleeding risk 1

Antidiabetic Agents

  • Insulin: reduce dose by 30-50% due to decreased renal clearance 1, 2
  • Sulfonylureas: avoid renally-excreted agents; use liver-metabolized alternatives with caution 1
  • DPP-4 inhibitors: significant dose reductions required (alogliptin to 6.25 mg daily, sitagliptin to 25 mg daily) 2
  • SGLT2 inhibitors: most not recommended for initiation; dapagliflozin may continue until dialysis for cardiovascular/kidney benefits 2

Analgesics

Opioids:

  • Safe options: methadone, fentanyl, sufentanil (minimal renal clearance) 4
  • Use with extreme caution: hydromorphone, oxycodone (monitor closely) 4
  • Avoid: morphine, codeine (toxic metabolite accumulation) 4
  • General principle: reduce dose when GFR <60 mL/min/1.73 m² 1

Chemotherapeutic Agents

  • Cisplatin: avoid when GFR <30 mL/min/1.73 m² 1
  • Melphalan: reduce dose 1
  • Methotrexate: avoid if possible 1

Multiple myeloma agents with NO dose adjustment needed:

  • Pomalidomide, carfilzomib, ixazomib, daratumumab, isatuximab, teclistamab 7

Critical Timing Principle

All medications should be administered AFTER hemodialysis on dialysis days to:

  • Prevent premature drug removal during dialysis
  • Facilitate directly observed therapy
  • Optimize drug levels 5, 6

Common Pitfalls

  1. Assuming hepatically-metabolized drugs are always safe: Some have active metabolites that accumulate (e.g., pyrazinamide) 5

  2. Not monitoring drug levels: Therapeutic drug monitoring is essential for aminoglycosides, cycloserine, ethambutol, and injectable TB agents 5, 6

  3. Continuing pre-dialysis doses: Many patients receive inappropriately high doses; 20-30% of dialysis patients are exposed to potentially inappropriate medications 8, 9

  4. Forgetting about drug interactions: Dialysis patients average 10-12 medications, creating high interaction risk 9

  5. Not adjusting for peritoneal dialysis: Drug removal differs from hemodialysis; use hemodialysis recommendations as starting point with serum concentration monitoring 5, 6

References

Research

Opioids in renal failure and dialysis patients.

Journal of pain and symptom management, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.